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Abstract
Abbreviations: AC -  acetylcholyne; AF -  atrial fibrillation; AP -  action potential; BLM -  bi-lipid membrane; DPA -  
Dimethylphenylacetamide; VA -  ventricular arrhythmia
Introduction: The study aim was to identify essential elements of the antiarrhythmic action mechanism of tertiary and 
quaternary derivatives of Dimethylphenylacetamide.
Materials and Methods: The study was conducted in albino rats and mice of both sexes; isolated neurons of mollusc 
Limnea stagnalis; and strips of rats’ right ventricle myocardium. Two compounds of Dimethylphenylacetamide LKhT- 
3-00 and LKhT-12-02 were studied. The cholynolytic property of the compounds was investigated by using a Schallek 
method in the authors’ modification. The adrenotropic activity of the derivatives was explored by Moore and Spear 
(1984), as well a by the method of catecholamine level detection in heart tissue. The permeability of derivatives through 
BLM was evaluated experimentally and theoretically. The derivatives’ influence on Na+-current was studied directly 
and indirectly.
Results and Discussion: Neither tertiary nor quaternary derivatives possess the cholynolytic property. LKhT-3-00 
prevented an increase in the adrenaline concentration in the left ventricle myocardium. The compounds prevent cate­
cholamine arrhythmia and conductivity disorders. LKhT-3-00 like Lidocaine passes through the BLM of the cardiac 
cell in an ionised form, whereas the quaternary derivative permeates cardiac cell membrane in an electro-neutral form. 
Lidocaine derivatives restrain acute ischemia-induced oxidative process growth in the cardiac muscle. Simultaneously, 
the LKhT-3-00 compound can activate antioxidant mechanisms and prevent acidosis and optimise the balance between 
[O2] and [CO2] concentrations in coronary dark blood. At a concentration of 10 mg/ml, although the derivatives reduce 
the amplitude of the leading edge of AP and its rate of increase, they do not, however, affect the duration of AP.
Conclusions: The compounds possess the Na+-blocking and cell-protecting properties. They do not affect K+-current 
through Kv4.3-channels.
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Introduction
Antiarrhythmic drugs have been in use for over 100 years 
to prevent and treat heart rhythm disorder despite many li­
mitations and adverse effects (Castro et al. 2015). Their role 
of being the essential part of antiarrhythmic therapy inspi­
res researchers to create novel molecules all over the world.
The mechanism of action is the cornerstone, which 
determines the therapeutic effectiveness and safety pro­
file of an antiarrhythmic drug. It might be defined as an 
assembly of functional transformations of intracellular 
homeostasis and extracellular interaction that ultimately 
determines the pharmacological property of a drug.
In the early 2000s in Russia, a few novel molecules, 
DPA (Lidocaine) derivatives, were synthetised (Sernov et 
al. 2005). The main reason for developing the substances 
was the short duration of Lidocaine therapeutic activity, 
which makes it impossible to administer the drug orally 
for prophylaxis (Collinsworth et al. 1974).
Lidocaine chemical modification was conducted in 
two ways. The simplest and less expensive one resulted 
in producing tertiary DPA derivatives. Having their base 
unchanged, they had the anionic part of their molecu­
le modified from nonorganic to amino acid or carbonic 
acid-containing fragments (Blinov et al. 2004). The more 
complicated way of chemical modification was a more 
complex synthesis, conducted on the basis of compu­
ter prognosis of structure-toxicity and structure-activity 
(Blinov et al. 2014).
The substances, representatives of both methods of 
chemical modification, have been experimentally studied 
for many years at The All-Russia Research Centre For 
Safety of Biologically Active Compounds (Sernov et al. 
2005), Ogarev Mordovia State University (Blinov et al. 
2004, Blinov et al. 2014, Blinova et al. 2015) and Tver 
State Medical University (Marasanov et al. 2013a, Ma- 
rasanov et al. 2013b).
The studies showed that modification of the DPA mo­
lecule anion fragment leads to a decrease in acute toxicity 
of the novel substance when administering parenterally 
and, maintaining the initial antiarrhythmic level of Lido­
caine activity, the duration of the pharmacological effect 
increases (Blinov et al. 2014). In particular, such conclu­
sions were made when studying the derivatives contai­
ning remains of L-Glutamic, N-Acetyl-L-Glutamic and 
Succinic acid as anion fragments of the molecules (Blin­
ov et al. 2004), whereas some substances, particularly 
those with the remains of L-Arginine, Acetylcysteine and 
Glycine as anionic groups demonstrated no substantial 
effect when compared with the structural analogue. Mo­
reover, they would lose their antiarrhythmic property. In 
addition, it should be emphasised that an increased effect 
duration is accompanied by the molecule haemodynamic 
profile optimisation (Balashov et al. 2005).
Quaternary DPA derivatives were produced by targe­
ting the nitrogen of the aliphatic fragment of the molecu­
le by analogy with developing a national antiarrhythmic 
drug quaternin, which is a quaternary allylmorpholinic
derivative of Trimethylphenylacetamide (Balashov et al. 
2005). The new substance appeared to be more active 
than Lidocaine and possessed a promising antiarrhythmic 
effect. However, one of the weak points of the compound 
was its higher toxicity in comparison with the structural 
ancestor.
Though, along with studying the effects of the com­
pounds, different opinions about possible mechanisms 
of the derivative therapeutic action have been expressed, 
no complete and logically structured study has ever been 
conducted, which ultimately filled the authors with deter­
mination to conduct the current study.
The study aim was to identify the essential mechanism 
of antiarrhythmic action of tertiary -  containing L-Gluta­
mic acid remains -  and quaternary allylmorpholinic DPA 
derivatives.
Materials and Methods
The protocols of the laboratory experiments included in 
the study underwent an ethical review at a meeting of the 
Local Ethical Committee of the Medical Institute of Og­
arev Mordovia State University (minutes №5 of 22 Oc­
tober 2003).
Animals and Biological Materials
Experiments were made in 84 albino male and female 
rats with an average weight 193.0 ± 4.2 g, 112 albino 
mice of both sexes with average weight 18.4 ± 1.5 g, 60 
papillary muscular strips isolated from albino rats’ right 
ventricles and 12 gigantic neurons of mollusc Limnea 
stagnalis parapharyngeal ganglion. The animals and bio­
logical material were purchased at the “Stolbovaya” and 
“Electrogorskiy” Departments of The Russian Research 
Centre for Biological Technologies and The Institute of 
Cell Biophysics of The Russian Academy of Sciences and 
maintained under required conditions at the University 
Novel Medication Research Centre. In case of invasive 
manipulation, all animals were obligatorily anaesthetised 
with either Ether inhalation or by iv administration of 
Urethane or Thiopental-sodium.
Substances and Drugs
Two novel pharmacologic substances, developed at The 
All-Russian Research Centre for Safety of Biological­
ly Active Compounds (Sernov et al. 2005) and Ogarev 
Mordovia State University (Blinov et al. 2014), were in­
vestigated (Fig. 1 contains chemical structures of the sub­
stances) in the form of fine white water-soluble powder 
without or with insignificant odour. To validate the phar­
macologic methods used in the laboratory and to com­
pare the obtained results with those for the references, 
some reference drugs were used, above all the chemical 
precursor of lidocaine -  hydrochloride. When modelling 
acetylcholine disturbances of the cardiac rhythm, the re-
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Figure 1. Chemical structures of DPA compounds
ference drug used was the natural alkaloid atropine. When 
studying the adrenergic component in the mechanism of 
cardiotropic action of tertiary and quaternary dimethylp- 
henylacetamide (lidocaine) derivatives, P12-adrenobloc- 
ker propranolol was used as a reference drug. To repro­
duce the acetylcholine arrhythmia, acetylcholine chloride 
(SIGMA company, Germany) was used; the induction of 
aconitine rhythm disturbances in the cardiac activity was 
carried out with the help of alkonoid aconitin from the 
same manufacturer.
Experimental methods
The role of the cholinergic influence on the derivati­
ves antiarrhythmic actions was identified in a model of 
AC-induced AF (David and Chick 1951) in the modifi­
cation in rats. The level of antiadrenergic activity of the 
compounds was measured in the experiments in mice by 
using the Moore et al. (1986) method (Moore and Spear 
1984). Epinephrine and Norepinephrine concentration 
in cardiac tissue of rats with acute myocardial ischemia 
was detected fluorimetrically. The antioxidant activity of 
LKhT-3-00 and LKhT-12-02 was explored by induced 
chemical luminescence.
To study the mechanisms of membrane permeabi­
lity, the BLM permeability coefficients for tertiary and 
quaternary dimethylphenylacetamide derivatives in the 
form of ions were measured. By measuring the ion per­
meability index, BLM permeability was assessed for 
the derivatives as ions. The BLM permeability for the 
compounds under study as ion pairs (neutral compounds)
was calculated theoretically -  presuming that, as well 
as for non-electrolytes, BLM permeability depended on 
the hydrophobic property of the substance. Permeability 
was estimated by a change in the refractivity of isola­
ted preparations of the right ventricular heart tissue of 
male rats. The permeability of the lipid membrane for 
ions -  tertiary and quaternary dimethylphenylacetamide 
derivatives -  was determined by the current magnitude of 
a short-circuit occurring in response to adding the com­
pound on one side of the membrane.
The effect of the test compounds in vitro on the depo­
larisation rate of the leading edge of the action potential 
(Vmax), on the amplitude of the action potential and on 
the duration of the action potential was studied in experi­
ments on papillary muscles (Sakmann and Neher 2009). 
The effect of dimethylphenylacetamide (Lidocaine) deri­
vatives on the activity of potassium channels was studied 
by recording the action potentials on gigantic neurons 
isolated from the peripheral ganglionic ring of the mol­
lusc Limnea stagnalis by the patch-clamp method (Bey­
der et al. 2012).
In experiments in isolated papillary muscular stri­
pes, the authors studied how the compounds affected AP 
duration, its front extent and velocity of depolarisation 
(Vmax) (Sakmann and Neher 2009). The potassium current 
through Kv4.3-channels was assessed by the patch-clump 
method in gigantic neurons of Limnea stagnalis mollusc’s 
parapharyngeal ganglion (Beyder et al. 2012).
The significance of the obtained results was estimated 
with modern statistics methods using licensed PC inter­
face “BioStat”, SPSS on a MacBook Air laptop (USA).
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Results and Discussion
At the first stage of the study, the preventative and thera­
peutic activities of the compounds were assessed on the 
model of aconitin-induced AF (Fig. 2). According to the 
method description, a few seconds after AC iv arrhythmo- 
gen infusion and a simultaneous mechanical irritation of 
the atrium, the onset of arrhythmia was observed lasting 
536±12 under control (Fig. 2). In all the experiments, 0.1 
mg/kg Atropine Sulphate iv, either before or immediately 
after the arrhythmia commencement, prevented or con­
trolled it. Unlike Atropine, both compounds when infused 
iv demonstrated no significant results. Thus, it could be 
concluded that tertiary and quaternary DPA derivatives 
possessed no cholynolytic activity.
Two approaches were used to evaluate the LKhT-3- 
00 and LKhT-12-02 sympathicotropic activity. The first 
one, similar to that mentioned above, allowed the authors 
to assess the pharmacological effectiveness of the deri­
vatives in preventing Epinephrine-induced arrhythmia in 
mice in comparison with Propranolol (Table 1).
Both derivatives prevented considerably reduced chan­
ces of development of Epinephrine-induced arrhythmia 
caused by iv administration of 100 pg/kg Epinephrine 
with simultaneous Halothane tracheal instillation, there­
fore demonstrating an effect similar to Propranolol. It was 
only the tertiary compound LKhT-3-00 which not only 
had an arrhythmic effect, but also increased the survival 
rate and life expectancy in mice.
The other way to evaluate antiadrenergic activity of 
DPA derivatives was to detect the level of Epinephrine 
and Norepinephrine in the myocardial tissue of rats with 
acute ischemia. When an occlusive syndrome develops in 
the myocardium of the ischemia zone, the concentration 
of both adrenaline and norepinephrine increases (Table 2).
Quaternary DPA compound LkhT-12-02, when admi­
nistered in a dose of 4.1 mg/kg iv, had no effect on the 
hormones’ concentration in the heart tissue. Tertiary DPA
compound LkhT-3-00, in a dose of 8.3 mg/kg, can inhibit 
the growth of the level of norepinephrine in the dama­
ged area with preventative intravenous administration, 
without affecting the concentration of adrenaline. And 
taking into account the fact that norepinephrine in the 
myocardium is predominantly synaptic in origin, unlike 
adrenaline coming from the blood plasma, it is reasonable 
to assume that compound LKhT-3-00 has some adrener­
gic properties, which can be realised indirectly through 
exciting glutamate NMDA receptors of cardiomyocytes, 
which are functionally linked with beta-l-adrenergic re­
ceptors (Zhenglin et al. 2012).
An extremely important element, ensuring the phar­
macological effect of antiarrhythmics, is its interaction 
with the cytoplasmic membrane of the cardiomyocyte. It 
does have particular importance for DPA derivatives as 
they likely block sodium channels. Sodium current bloc­
kers are known to block the sodium channels from the 
inside of the heart cell membrane and so, to be effective, 
they should penetrate well through the lipid bilayer (Be­
cker and Reed 2006). The permeability of dimethylphe­
nylacetamide (Lidocaine) derivatives through BLM was 
assessed by the change in the refractivity of the myocar­
dium strips of the right ventricle of the rat’s heart, perfu­
sed with solutions of the compounds (Fig. 3).
As a result, Lidocaine, as well as its derivatives, pro­
longed the refractory period of myocardial strips; therefo­
re both tertiary and quaternary dimethylphenylacetamide 
(lidocaine) derivatives penetrate through the membrane. 
However, to evaluate membrane permeability, it became 
critical to compare the change rate of the myocardial tis­
sue refractory with the estimated velocity of the deriva­
tives entering a cell, assuming that the membrane lipid 
bilayer limited the flow of the derivatives. When carrying 
out the calculations, it was found that, while the refracti- 
vity change rate for tertiary derivative of LKhT-3-00 cor­
responded to the rate of entry into the cell (proportional to 
the extraction coefficient from the octanol-water system),
Table 1. Evaluation of Anti-adrenergic Effect of Tertiary and Quaternary DPA derivatives in experiments on anaesthetised mice
No Pharmacologic agent Dose
(mg/kg)
Number of animals Life du­
ration, 
min, 
M±SD
Total VA CCD Dead
1 Control group - 8 8 8 8 12±2
2 Propranolol 5.0 8 2# 3# 5 27±2*
4 Lidocaine 10.0 8 3# 8 7 13±2A
5 LKhT-3-00 8.3 8 2# 5 3# 21±3*
6 LKhT-l2-02 4.1 8 3# 6 7 14±3A
Note: VA -  ventricular arrhythmia, CCD -  cardiac conduction disease;
# -  differences when comparing the results with the “Control group” results are significant at p <0.05, Fisher’s exact test;
* -  differences when comparing the results with “Control group” results are significant at p <0.05;
а -  when compa ring with the “Propranolol”group, the differences are statistically significant at p <0.05 (analysis of the survival 
curves using the Gehan criterion with Yates’ correction).
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Table 2. Determination of Epinephrine and Norepinephrine in Myocardium of Rats’ hearts during Experimental Ischemia with 
Administration of DPA derivatives
CJ
§ Test unit
-C
Experimental group
Control group, pM/g LKhT-12-02, pM/g LKhT-3-00, pM/g
RZ LV
iz  lv
О
LA
0.43±0.06
1.23±0.13*
0.81±0.15
0.47±0.12
0.98±0.09*
0.78±0.08
0.39±0.10
0.82±0.17*
0.84±0.12
RZ LV
iz  lv
W  e .
LA
0.35±0.08
0.96±0.09*
0.49±0.10
0.33±0.05
0.76±0.17
0.53±0.08
0.37±0.06
0.44±0.07#
0.45±0.11
Note: LV -  left ventricle, LA -  left atrium, RZ -  remote zone, IZ -  ischemic zone;
* -  statistical significance of the differences when compared with the “LV group” at p <0.05 is determined using a one-dimensional 
analysis of variance and the subsequent application of the Newman-Keuls criterion;
# -  statistical significance of the differences when compared with the “Control” group at p <0.05 is determined using a one-dimen­
sional analysis of variance and the subsequent application of the Newman-Keuls criterion.
for the quaternary derivative of LKhT-12-02, no such re­
gularity in the ionised form was established. At the same 
time, the issue of membrane permeability for charged mo­
lecules of quaternised drugs has long been debated both 
in foreign and national literature. Sunami et al. (2000) 
and Tsuchia and Mizogami (2013) proposed a different 
variant of transporting charged derivatives -  transporting 
them in an electrically neutral form. Such a possibility 
was repeatedly discussed in literature; however, there has 
been no single point of view on this topic formed.
According to such an approach, the authors considered 
an ion pair in a membrane as a neutral molecule of no­
nelectrolyte composed of the charged quaternary dimet- 
hylphenylacetamide (Lidocaine) derivative LKhT-12-02 
under study and the basic electrolyte anion Cl-. The sub­
sequent calculation proved the assumption that LKhT-12- 
02 permeates through the cardiomyocyte membrane in 
the electro- neutral form -  in the form of ion pairs.
The functional condition of trans-membrane ion chan­
nels amongst other factors depends on a membrane mi­
crostructure at a given moment of time. The membrane 
fluidity or rigidity depends on the functioning of free ra­
dical peroxidation systems and anti-oxidation protection.
The influence of tertiary and quaternary DPA derivatives 
was explored on lipid peroxidation processes in the rat’s 
heart myocard in a model vitelline system (Table 3).
It was found that the prophylactic iv administration of 
the derivatives and the reference drug of Lidocaine in­
hibits the activation of free radical lipoperoxidation in 
response to the development of ischemic syndrome. A 
similar effect for Lidocaine has already been described 
in foreign scientific periodicals (Kaczmarek et al. 2009, 
Lenfant et al. 2004). Besides, it should be that the terti­
ary compound of LKhT-3-00 can simultaneously activa­
te the antioxidant membrane systems which, in case of 
an occlusal syndrome, would restore the balance of the 
systems of cardiomyocyte membranes under study. In the 
experiments on rats with occlusion of the coronary artery, 
it was also confirmed that LKhT-3-00, when administered 
iv in a dose of 8.3 mg/kg, corrected acidosis and norma­
lised the ratio of the partial oxygen tension and carbon 
dioxide in the blood of the coronary venous sinus.
At the final stage of the study, it was extremely im­
portant to investigate how DPA compounds influenced 
sodium and potassium ion currents. First of all, an indi­
rect way was used to assess Na+-blocking activity of the
Figure 2. Average duration of AC-induced AF with preventative (1) and controlling (2) iv administration of atropine sulphate (A), 
compound LKhT-3-00 (B), compound LKhT-12-02 (C); D -  control group of animals
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compounds on the aconitin model of arrhythmias. There, 
the expected results were obtained proving that both deri­
vatives prevented the generation of aconitine arrhythmia 
at a wide range of doses and, in terms of the therapeutic 
effect range, they were not inferior, but rather superior 
to the reference preparation Lidocaine. In experiments in 
mice with Aconite-induced arrhythmia, both compounds 
like Lidocaine demonstrated dose-dependent antiarrhy­
thmic effects.
Moreover the antiarrhythmic index, calculated on ba­
sis of the results, showed the compounds effectiveness in 
doses less than that of Lidocaine.
In the experiments on isolated strips of the right ventri­
cle myocardium of the heart of rats, the changes in some 
AP parameters against perfusion with solutions contai­
ning compounds LKhT-3-00 and LKhT-12-02 (Fig. 4) 
were studied.
Thus, at 10 mg/ml concentration of LKhT-3-00 and 
LKhT-12-02, the AP front extent and depolarisation velo­
city (V ) were lowered. At the same time, none of the 
compounds affected the AP duration measured at 80% 
depolarisation level. Obtained results proved the anti-Na+ 
activity of the DPA derivatives and their K+-blocking 
properties were made doubtful.
Both substances reduced the AP amplitude and sup­
pressed the rate of increase of its leading edge. At the 
same time, no experiment demonstrated an increase in 
the AP duration, measured at 80% repolarisation level. 
The obtained results proved the anti-Na+ activity of the 
compounds and questioned the ability of the compounds 
to suppress or activate the potassium current.
To test this type of activity, the “patch-clamp” tech­
nology was used -  a method of recording the potential 
of single potassium channels of a giant neuron isolated 
from the peripheral ganglionic ring of a large mollusc 
Limnea stagnalis. The potassium channels of this neuron 
are channels of delayed rectification of type Ky4.3, inclu­
ding those present in the myocardium of warm-blooded
Lidocaine TPA* LKhT-3-00 LKhT-12-02
Figure 3. Relative increase in the refractivity of the ventricular heart tissue of the rat (in % of the original value) affected by: 15 gM 
lidocaine (n = 5), 50 gM trimecaine (n = 4), 5 gM LHT-12-02 (n = 6) and 30 gM LHT-3-00 (n = 5)
Note: mean refractivity in the control: 92 ± 3 (lidocaine), 90 ± 7 (trimecaine), 94 ± 8 (LKhT-12-02) and 96 ± 4 ms (LKhT-3-00). 
The average values and root-mean-square deviations are provided. On the abscissa -  the time of registration of parameters in min.
* -  according to O.G. Agenosova.
Table 3. Correlation of Pro-oxidant / antioxidant Potential of Cardiomyocyte Membranes of Rat’s Hearts with Acute Myocardial 
Infarction, with Dimethylphenylacetamide (Lidocaine), Derivatives Being Preventatively Administered
Location
Attack intensity, imp/sec Drug, dose (mg/kg)
LA LV RZ LV IZ
Oxidative process
Control group 
Lidocaine, 7.6 
LKhT-3-00, 3.8 
LKhT-12-02, 1.9
4.77±1.24
4.81±1.12
5.01±0.83
4.96±1.29
12.8±0.97
11.9±1.04
9.94±1.13
10.5±0.76
48.5±3.23
31.5±1.18*
30.3±1.15*
35.7±0.96*
Control group 3.13±0.54 3.9±0.41 14.9±1.17
Antioxidant activity
Lidocaine, 7.6 3.26±0.42 4.1±0.67 16.3±2.05
LKhT-3-00, 3.8 3.09±1.01 4.3±1.15 27.3±2.084
LKhT-12-02, 1.9 3.17±0.23 3.7±0.94 15.3±1.73
Note: LA -  left atrium, LV -  left ventricle, RZ -  remote zone, IZ -  ischemic zone;
* -  when compared with the control group, the results are statistically significant at p <0.05 (single-factor analysis of variance, 
Newman-Keuls criterion);
q -  In comparison with the control group, the “Lidocaine” and “LKhT-12-02” groups, the results are statistically significant at 
p <0.05 (single-factor analysis of variance, Newman- Keuls criterion).
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Figure 4. Effect of dimethylphenylacetamide derivatives (at a concentration of 10.0 mg/1) on AP (upper curve) and Vmax (bottom 
curve) of the papillary muscle of the rat’s right heart ventricle
Figure 5. Records of currents through potassium channels of the neuron of the Limnea stagnalis mollusc in a “whole-cell” configuration
mammals and humans. The experiments were carried out 
in the Laboratory of Cellular Neurobiology of the Institu­
te of Cell Biophysics of the Russian Academy of Scien­
ces, in collaboration with Ph.D., Senior Research Fellow, 
Maksim E. Astashev.
Cells dialysis was carried out with a solution contai­
ning the test derivatives in a concentration range of 10-6 to 
10-4M. In none of the cells under study (inside-out, single 
attached cell), neither the tertiary dimethylphenylaceta-
mide (Lidocaine) derivative nor the quaternary derivative 
changed the functional activity of potassium channels 
(Fig. 5).
Experiments were conducted in scientific collabora­
tion with Dr. M.E. Astashev1. The authors dialysed the 
cell with the derivative-containing solution from 10-6 up
1 Laboratory of Cell Neurobiology of The Institute of Cell Biophysics, 
Russian Academy of Sciences
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to 10-4 M concentrations in the following configurations: 
“whole cell”, “inside-out” and “single-attached cell”. As 
a result, neither tertiary derivative LKhT-3-00 nor qua­
ternary compound LKhT-12-02 blocked the K+-current 
while it was applied to the inside or outside surface of the 
channel-containing membrane.
Conclusions
According to the obtained data, the following conclusions 
can be made:
1. Both tertiary dimethylphenylacetamide (Lidocaine) 
derivative containing remains of L-Glutamic acid and 
quaternary Allylmorpholine DPA compound have no 
cholinergic properties. Tertiary derivatives LKhT-3-00 
demonstrate an Epinephrine-negative effect, prevent­
ing Epinephrine-induced arrhythmia and experimental 
animals’ mortality as well as lowering an ischemia-me­
diated increase of Norepinephrine concentration in the 
heart tissue of rats.
2. LKhT-3-00 pass through the cardiac cell BLM in an 
ionised form whereas molecules of quaternary dimeth- 
ylphenylacetamide (Lidocaine) derivative LKhT-12- 
02 permeate the membrane as an ion pair in an elec­
tro-neutral condition.
3. Both tested derivatives restrain the lipid peroxidation 
process in the ischemic myocardium of rats, but only
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